Format

Send to

Choose Destination
Epigenetics. 2017 May 4;12(5):323-339. doi: 10.1080/15592294.2016.1265710. Epub 2016 Dec 2.

Bromodomain inhibitors and cancer therapy: From structures to applications.

Author information

1
a Cancer Epigenetics and Biology Program (PEBC) , Bellvitge Biomedical Research Institute (IDIBELL) , Barcelona , Catalonia , Spain.
2
b Department of Physiological Sciences II, School of Medicine , University of Barcelona , Barcelona , Catalonia , Spain.
3
c Institució Catalana de Recerca i Estudis Avançats (ICREA) , Barcelona , Catalonia , Spain.

Abstract

Aberrations in the epigenetic landscape are a hallmark of cancer. Alterations in enzymes that are "writers," "erasers," or "readers" of histone modification marks are common. Bromodomains are "readers" that bind acetylated lysines in histone tails. Their most important function is the regulation of gene transcription by the recruitment of different molecular partners. Moreover, proteins containing bromodomains are also epigenetic regulators, although little is known about the specific function of these domains. In recent years, there has been increasing interest in developing small molecules that can target specific bromodomains. First, this has helped clarify biological functions of bromodomain-containing proteins. Secondly, it opens a new front for combatting cancer. In this review we will describe the structures and mechanisms associated with Bromodomain and Extra-Terminal motif (BET) inhibitors and non-BET inhibitors, their current status of development, and their promising role as anti-cancer agents.

KEYWORDS:

Acetylation; bromodomain and extra-terminal motif inhibitors; cancer; epigenetics; histone marks

PMID:
27911230
PMCID:
PMC5453193
DOI:
10.1080/15592294.2016.1265710
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center